GENOME CAPITAL

We are company builders passionate about innovative HealthTech
About Us
Our team is a rare combination of PhD scientists, tech enterpreneurs and M&A dealmakers with an exceptional investment experience including work in teams who identified and raised 4 unicorns and leadership of 5,000+ tech founders' community that is part of a unique ecosystem raised more than 80 unicorns.
About Us
Our team is a rare combination of PhD scientists, tech enterpreneurs and M&A dealmakers with an exceptional investment experience including work in teams who identified and raised 4 unicorns and leadership of 5,000+ tech founders' community that is part of a unique ecosystem raised more than 80 unicorns.
Our Focus
We invest capital and expertise in talented teams and exciting science and technology.
We invest capital and expertise in talented teams and exciting science and technology.
Our focus

Healthcare costs continue to grow at a rapid pace. Genome Capital believes that now is the right time to invest in:

Healthcare costs continue to grow at a rapid pace. Genome Capital believes that now is the right time to invest in:

robotics med equipment
accessible diagnostic
telemedicine
med devices
3D Printing
robotics med equipment
accessible diagnostic
telemedicine
med devices
3D printing

That can expand the foundations of medical practice, improve the quality of life and provide high returns for our investors.

That can expand the foundations of medical practice, improve the quality of life and provide high returns for our investors.

Acceleration and ecosystem development
Acceleration and ecosystem development
The Gulf countries identified the HealthTech as a priority.
UAE Mubadala Health is committed to deliver its vision of transforming the regional healthcare landscape.

KSA Ministry of Health is working on implementing a highly ambitious program; in order to achieve its innovative vision for e-health: "safe, efficient health system, based on the care centered on a patient,
standard-oriented, and supported by the e-health".
The Gulf countries identified the HealthTech as a priority.
UAE Mubadala Health is committed to deliver its vision of transforming the regional healthcare landscape.

KSA Ministry of Health is working on implementing a highly ambitious program; in order to achieve its innovative vision for e-health: "safe, efficient health system, based on the care centered on a patient,
standard-oriented, and supported by the e-health".

We are developing an ecosystem of HealthTech in MENA by accelerating biotech, digital and robotics focused companies. We provide experts advising, tech founders network and access to funds.

We are developing an ecosystem of HealthTech in MENA by accelerating biotech, digital and robotics focused companies. We provide experts advising, tech founders network and access to funds.

Impact
Impact
We believe that high financial and societal returns can coexist.
More than 5 bn people in emerging markets have limited access to medical services due to shortage of doctors in the region, lack of good infrastructure, and high cost of services and medicines.
New technologies in Life Science, IT and Robotics can change the rules of the game!
We believe that high financial and societal returns can coexist.
More than 5 bn people in emerging markets have limited access to medical services due to shortage of doctors in the region, lack of good infrastructure, and high cost of services and medicines.
New technologies in Life Science, IT and Robotics can change the rules of the game!

Our Team
  • Svetlana Gavrilova
    Managing Partner
    • Master in Economics and Law (MSU)
    • Founders Institute (USA), ACCA (UK) alumni
    • 7 years in HealthTech VC fund Rusnano ($500MM AUM)
    • 7 years in KPMG audit
    • Principal of 5,000-member global tech founders' community
    • Business angel in BioTech
    LinkedIn
  • Anton Melnikov
    Venture Partner
    • MBA, Bachelor of Technology (NSU)
    • 10+ year in C-level and internation BD positions for HealthTech companies
    • HealthTech Startups mentor in Skolkovo
    • 5+ years in supervisery Board member for Siberian science cluster

    LinkedIn
  • Veronika Aksenova
    Venture Partner
    • PhD in molecular biology (France)
    • 6+ years of experience in R&D
    • BioTech VC Skolkovo
    • 4+ Leading onco products director at Roche
    • Mentor in Founder Institute for Impact and Sustainability startups
    • BioTech leader of 5,000-member tech founders' community
    LinkedIn
  • Sadyk Gusniev
    Venture Partner
    • MD, Head & Neck Cancer (Universit√© Paris-Sorbonne)
    • MBA in Pharmaceutical Management
    • 7+ years on leadership positions in Pharma & Biotech (Bayer, Sanofi, Ipsen)
    • Head of Biotechnology in Rusnano Management Company
    • Specialization in biotech scientific due diligence
    • Harvard Biotech Incubator (2021)
    • MIT The Science & Business in Biotechnology (2021)
    • Business accelerators advisory board member
    Linkedin
Our Team
  • Svetlana Gavrilova
    Managing Partner
    • Master in Economics and Law (MSU)
    • Founders Institute (USA), ACCA (UK) alumni
    • 7 years in HealthTech VC Rusnano ($500MM AUM)
    • 7 years in KPMG audit
    • Principal of 5,000-member global tech founders' community
    • Business angel in BioTech
    LinkedIn
  • Anton Melnikov
    Venture Partner
    • MBA, Bachelor of Technology (NSU)
    • 10+ years in C-level and internation BD positions for HealthTech companies
    • HealthTech Startups mentor in Skolkovo
    • 5+ years in supervisery Board member for Siberian science cluster
    LinkedIn
  • Veronika Aksenova
    Venture Partner
    • PhD in molecular biology (France)
    • 6+ years of experience in R&D
    • BioTech VC Skolkovo
    • 4+ Leading onco products director at Roche
    • Mentor in Founder Institute for Impact and Sustainability startups
    • BioTech leader of 5,000-member tech founders' community
    LinkedIn
  • Sadyk Gusniev
    Venture Partner
    • MD, Head & Neck Cancer (Universit√© Paris-Sorbonne)
    • MBA in Pharmaceutical Management
    • 7+ years on leadership positions in Pharma & Biotech (Bayer, Sanofi, Ipsen)
    • Head of Biotechnology in Rusnano Management Company
    • Specialization in biotech scientific due diligence
    • Harvard Biotech Incubator (2021)
    • MIT The Science & Business in Biotechnology (2021)
    • Business accelerators advisory board member
    Linkedin

News
News

Speak With Us
Meet the Partners to learn more about GENOME CAPITAL.
First name
Last name
Email
Please select what does best describe you?
Apply your project
Speak With Us
Meet the Partners to learn more about GENOME CAPITAL.
First name
Last name
Email
Please select what does best describe you?
Apply your project
Subscribe to the mailing list
Subscribe to the mailing list
Contacts
Veronika Aksenova
Svetlana Gavrilova